Author Interviews, Mental Health Research, Schizophrenia / 07.11.2025
Edinburgh Study Suggests Doxycyline May Abate Progression of Schizophrenia in Adolescents
MedicalResearch.com Interview with:
Ian Kelleher PhD, MB BCh BAO (Medicine)
Professor of Child and Adolescent Psychiatry
Academy of Medical Sciences Professor
Institute for Neuroscience and Cardiovascular Research
University of Edinburgh
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Schizophrenia is a severe mental illness associated with hallucinations, delusions and a marked decline in functioning. It usually begins in adulthood, in the 20s, but we know from recent research that as many as half of all individuals who develop schizophrenia had attended child and adolescent psychiatry services earlier in life for other mental health problems. That’s exciting because it suggests: maybe there’s something we could do to reduce risk of schizophrenia in adolescent psychiatry services. But, at present, we don’t have evidence that any intervention reduces schizophrenia risk in this clinical population.
Lots of researchers are interested in the antibiotic doxycycline, and the structurally similarly minocycline, because it has potential neuroprotective effects. It crosses the blood brain barrier and seems to reduce inflammation and apoptosis (or programmed cell death). We think that excessive synaptic pruning may play a key role in the development of schizophrenia. In laboratory studies, doxycycline seems to reduce the level of synaptic pruning by its effect on the immune system. Some research suggests that even low dose exposure to doxycycline may lead to long-term effects in “dampening down” activity by microglia, the brain’s resident macrophages, which are central to the process of synaptic pruning.
(more…)